Paolo Santini, Roberto Pola. "Letter by Santini and Pola Regarding Article, “Rivaroxaban for 18 Months versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial)”." Circulation, 2025. doi:10.1161/circulationaha.124.073416